Alteogen’s inventory value plummeted on Dec. 5 following information that MSD’s subcutaneous (SC) formulation of Keytruda acquired a gross sales ban injunction in Germany. This occurred after a German courtroom accredited an injunction filed by Halozyme, a competitor of Alteogen.
Halozyme filed an injunction searching for to halt the distribution and gross sales of Keytruda SC, which Merck & Co. (MSD) has been promoting in Germany. In accordance with Halozyme, the seventh Civil Division of the Munich Regional Court docket discovered that there was imminent infringement of Keytruda SC associated to MDASE, one among Halozyme’s European patents.
Nonetheless, MSD can attraction this choice. Individually, the patent invalidation lawsuit that MSD filed in opposition to the MDASE patent in August is pending on the Federal Patent Court docket of Germany. There’s a chance that MSD’s injunction attraction and the patent invalidation lawsuit could possibly be consolidated sooner or later, probably invalidating the injunction.
MSD’s Keytruda SC is predicated on Alteogen’s platform expertise ALT-B4, which converts intravenous (IV) prescription drugs into subcutaneous (SC) formulations utilizing human hyaluronidase.
